Aetna GLP-1 Coverage for Weight Loss (2026)
You have an Aetna card and a straightforward question: will this plan pay for a GLP-1 medication to help you lose weight? If you have been searching for a while, you have probably noticed the answer keeps splitting in two. Some people with Aetna get coverage. Others with what looks like the same insurance get a flat no. Both experiences are real, because the answer does not live at the Aetna level. It lives in your specific plan.
Here is what Aetna’s own policies and formulary documents say as of 2026-10-16, including a formulary change that took effect October 1, 2026, and how to find out where your own plan stands.
Transformation Health is an independent guide, not a provider, and is not affiliated with Aetna or CVS Health: we do not prescribe, sell medication, or work with insurance. This content is for general education and is not medical advice. Talk with a licensed provider about your situation.
The short answer
Coverage depends on your specific plan. As of 2026-10-16, Aetna’s clinical policy on weight reduction states that many Aetna benefit plans specifically exclude coverage of weight reduction medications, and that on those plans, claims for weight loss drugs are denied based on that exclusion.[1] So the real question is not “does Aetna cover GLP-1s,” it is “does my plan include weight loss medications.” Some plans do. Many do not.
On plans that include the benefit and use the Aetna Standard Plan formulary, Zepbound was added to the formulary effective October 1, 2026.[2] Prior authorization applies to the weight loss GLP-1s, with criteria Aetna publishes in its pharmacy policies.[3][4]
GLP-1 medications prescribed for type 2 diabetes are a separate coverage category, with their own criteria. This page is about coverage for weight management.
How Aetna handles weight loss GLP-1s
Aetna is part of CVS Health, and Aetna’s formulary documents state that its pharmacy benefits are administered through an affiliated pharmacy benefits manager, CVS Caremark.[2] Where the weight loss benefit exists, Aetna publishes its prior authorization criteria in pharmacy clinical policy bulletins. As of 2026-10-16, the policies for Wegovy and for Zepbound list these adult criteria for weight management:[3][4]
| Question | What Aetna’s published documents say (as of 2026-10-16) |
|---|---|
| Are weight loss drugs covered on every plan? | No. Aetna states many of its benefit plans specifically exclude weight reduction medications[1] |
| Is Zepbound on the formulary? | Added to the Aetna Standard Plan formulary effective October 1, 2026[2]; employers can customize their formulary |
| If covered, is prior authorization required? | Yes[3][4] |
| Age | 18 or older |
| Lifestyle documentation | At least 6 months in a comprehensive weight management program (behavioral changes, reduced-calorie diet, more physical activity, with follow-up) before starting the drug |
| BMI criteria | Baseline BMI of 30 or higher, or 27 or higher with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or dyslipidemia) |
| First approval | 8 months |
| Renewal requirement | At least 3 months at a stable maintenance dose, and a loss of at least 5 percent of baseline body weight or keeping that initial 5 percent off; renewals are approved for 12 months |
Some plans use a stricter policy. A separate Aetna policy covering Wegovy, Zepbound, Saxenda, and Mounjaro for weight loss, dated January 2, 2026, requires a baseline BMI of 35 or higher for adults, along with the same 6-month weight management program requirement.[5] Which policy applies depends on your plan, and your plan documents are the only version that counts for you.
Saxenda. Aetna’s BMI 35 policy includes criteria for Saxenda.[5] We could not confirm Saxenda’s formulary status on Aetna’s standard formularies from a primary source, so check your plan’s drug list or ask member services.
What changed in 2025 and 2026
July 1, 2025. An Aetna exception policy dated July 1, 2025 listed Zepbound as non-formulary on the plans it covers, with Wegovy as the primary formulary alternative.[6] Members on Zepbound faced a switch, an exception request, or paying out of pocket.
May 28, 2026. CVS Health announced that CVS Caremark would add Zepbound back to its commercial formularies as an additional preferred option on October 1, 2026, for plan sponsors that elect to cover weight management medications, and said plan sponsors keep discretion to customize coverage.[7]
October 1, 2026. Aetna’s formulary update for the Aetna Standard Plan took effect. It lists Zepbound as added to the formulary and Foundayo (orforglipron), an oral GLP-1, as moving from non-preferred to preferred.[2]
The pattern to take away: formulary status is not permanent, and employers revisit their own plan decisions every plan year. A medication that is covered today can be non-formulary next plan year, and the reverse. A benefit you have this year is worth confirming again at open enrollment.
Aetna Medicare and individual plans
Aetna Medicare Advantage and Part D plans. Plans with Medicare drug coverage follow federal Part D rules. The law lets Part D exclude “agents when used for anorexia, weight loss, or weight gain,” so a GLP-1 prescribed for weight loss alone is generally not covered under basic Part D coverage.[8] Part D plans may cover a GLP-1 for another FDA-approved use, such as type 2 diabetes, and federal rules let plans offering enhanced alternative coverage add supplemental drug benefits.[9] Separately, CMS is running the Medicare GLP-1 Bridge, a demonstration from July 1, 2026 through December 31, 2027 that gives eligible Part D enrollees access to certain GLP-1 drugs for weight management outside the regular Part D benefit.[10] Ask your plan, and ask CMS or 1-800-MEDICARE whether the Bridge applies to you. Our page on Medicare Part D and GLP-1 coverage covers the details.
ACA marketplace plans. CVS Health said in May 2025 that Aetna would stop offering individual plans on the Affordable Care Act exchanges in 2026, as reported by Healthcare Dive.[11] If you buy your own coverage through the marketplace, your weight loss drug coverage depends on the plan you have now.
How to check your own plan in ten minutes
You do not need to guess, and you do not need to wait for a denial letter. Three routes, fastest first:
Ask your HR benefits team. If you have an employer plan, the single decisive fact is whether your plan includes weight loss medication coverage. HR or your benefits portal can answer that directly, and they can tell you whether the plan uses a customized formulary.
Call member services. Use the number on your Aetna card and ask three questions. Does my plan include coverage for weight loss medications? If so, which GLP-1 medications are on my formulary for weight management, including Zepbound after the October 1, 2026 update? And which prior authorization policy applies to my plan?
Check your prescription drug list. Log in to your member portal and search the drug list for semaglutide or tirzepatide. Read the indication notes carefully; a listing under diabetes coverage does not mean weight management is covered.
If the benefit exists on your plan, your next step is the paperwork. Our guide to GLP-1 prior authorization walks through the documentation these requests usually need, including the BMI record and the 6 months of weight management program participation that Aetna’s criteria ask for.
If your plan says no
Plenty of people with Aetna cards land here, through no fault of their own. What you do next depends on why the answer was no.
The denial was about criteria or documentation. This is often fixable. A documented baseline BMI, weight-related conditions noted explicitly in your chart, and recorded participation in a weight management program for at least 6 months address the criteria above. HealthCare.gov says you generally have 180 days from a denial notice to file an internal appeal, and if that appeal is denied, you can in many cases ask for an independent external review.[12][13] Start with our guide on what to do when insurance denies your GLP-1.
The medication you want is not on your formulary. Ask your plan how to request a formulary exception. Your prescriber’s documentation of why the formulary alternative is not appropriate for you is what carries the request. For individual and small-group plans that must cover essential health benefits, federal rules require an exception process, with a decision due within 72 hours on a standard request and within 24 hours when circumstances are urgent.[14] Employer plans follow different federal claim rules, and your plan documents state the exact limits that apply to you.
Your plan does not include the benefit. An appeal generally cannot override a plan exclusion, because the medication is not a covered benefit on your plan. You can ask HR whether weight loss coverage is under consideration for the next plan year, check whether another plan at open enrollment includes it, and ask your prescriber whether any covered indication applies to you. Beyond that, the options are outside insurance:
- Manufacturer savings and self-pay options. Novo Nordisk and Eli Lilly each publish savings and self-pay terms, and the terms change. Our page on GLP-1 savings programs compares them.
- Cash-pay telehealth programs. Some prescribe brand-name medications and some prescribe compounded medications. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products.[15] Our page on compounded GLP-1 without insurance explains how that route works.
Prices vary by program, medication, and dose. Compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms. At most telehealth programs, a licensed provider reviews your health history and decides whether a prescription is appropriate. The full insurance coverage overview can help you weigh the options side by side.
Transformation Health does not accept payment from providers. How we make money.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedCitations
[1] Aetna. Medical Clinical Policy Bulletin 0039, “Weight Reduction Programs and Devices” (includes the statement that many Aetna benefit plans specifically exclude coverage of weight reduction medications). Last review 03/10/2026. Accessed 2026-10-16. https://www.aetna.com/cpb/medical/data/1_99/0039.html
[2] Aetna. “Formulary Updates for Aetna Standard Plan effective October 1, 2026.” Accessed 2026-10-16. https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/individuals-families-health-insurance/document-library/pharmacy/SOC-for-10.01.26-Aetna-Standard-Plan.pdf
[3] Aetna. Pharmacy Clinical Policy Bulletin, “Wegovy PA with Limit 4774-C P08-2025 v5.” Dated August 20, 2026. Accessed 2026-10-16. https://www.aetna.com/products/rxnonmedicare/data/2026/Wegovy_PA_with_Limit_4774-C_P08-2025_v5.html
[4] Aetna. Pharmacy Clinical Policy Bulletin, “Zepbound PA with Limit 6192-C P08-2024 v4.” Dated August 27, 2025, posted in Aetna’s 2026 policy library. Accessed 2026-10-16. https://www.aetna.com/products/rxnonmedicare/data/2026/Zepbound_PA_with_Limit_6192-C_P08-2024_v4.html
[5] Aetna. Pharmacy Clinical Policy Bulletin, “Weight Loss (BMI 35) GIP-GLP-1, GLP-1 Agonists PA with Limit 6450-C P08-2025 v4.” Dated January 2, 2026. Accessed 2026-10-16. https://www.aetna.com/products/rxnonmedicare/data/2026/Weight_Loss_(BMI%2035)_GIP-GLP-1,_GLP-1_Agonists_PA_with_Limit_6450-C_P08-2025_v4.html
[6] Aetna. Pharmacy Clinical Policy Bulletin, “Zepbound Exception (ACCF, ACF, ACFC, SCCF, SF, SFC, VF, VFC) 6981-A P04-2025.” Dated July 1, 2025. Accessed 2026-10-16. https://www.aetna.com/products/rxnonmedicare/data/2025/Zepbound_Exception_(ACCF,_ACF,_ACFC,_SCCF,_SF,_SFC,_VF,_VFC)_6981-A_P04-2025.html
[7] CVS Health. “CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options” (company news release), May 28, 2026. Accessed 2026-10-16. https://www.cvshealth.com/news/company-news/cvs-caremark-delivers-affordability-and-access-to-glp-1-weight-management-medications-with-expanded-coverage-options.html
[8] 42 U.S.C. 1395w-102(e)(2)(A) (definition of covered Part D drug; exclusions). Accessed 2026-10-16. https://www.law.cornell.edu/uscode/text/42/1395w-102
[9] 42 CFR 423.104(f)(1) (enhanced alternative coverage; supplemental benefits). Accessed 2026-10-16. https://www.law.cornell.edu/cfr/text/42/423.104
[10] Centers for Medicare and Medicaid Services. “Medicare GLP-1 Bridge.” Accessed 2026-10-16. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
[11] Pifer Parduhn R. “CVS plans to exit ACA individual exchanges, strikes Wegovy deal with Novo Nordisk.” Healthcare Dive, May 1, 2025. Accessed 2026-10-16. https://www.healthcaredive.com/news/cvs-aetna-exit-aca-novo-nordisk-wegovy-deal/746833/
[12] HealthCare.gov (Centers for Medicare and Medicaid Services). “Internal appeals.” Accessed 2026-10-16. https://www.healthcare.gov/appeal-insurance-company-decision/internal-appeals/
[13] HealthCare.gov (Centers for Medicare and Medicaid Services). “External review.” Accessed 2026-10-16. https://www.healthcare.gov/appeal-insurance-company-decision/external-review/
[14] 45 CFR 156.122(c) (prescription drug benefits: standard and expedited exception requests). Accessed 2026-10-16. https://www.law.cornell.edu/cfr/text/45/156.122
[15] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” Accessed 2026-10-16. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Important disclosures
Coverage information on this page is current as of 2026-10-16, is general and educational, and changes frequently. It does not represent the terms of your specific plan and is not legal advice. Confirm current benefits, formulary status, and prior authorization requirements directly with Aetna: call the member services number on your insurance card, or ask your HR benefits team if you have an employer plan.
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. transformationhealth.com is a website operated by Amerigo Health LLC. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication, and does not give medical advice. A licensed provider decides whether a prescription is appropriate. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound and may differ in formulation, purity, and potency. Wegovy and Saxenda are trademarks of Novo Nordisk A/S. Zepbound, Mounjaro, and Foundayo are trademarks of Eli Lilly and Company. Aetna, CVS Health, and CVS Caremark are trademarks of their respective owners. Transformation Health is not affiliated with or endorsed by Aetna, CVS Health, Novo Nordisk, or Eli Lilly. Transformation Health does not accept payment from providers. How we make money.